OncoMatch/Clinical Trials/NCT05891561
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
Is NCT05891561 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pertuzumab for breast cancer.
Treatment: Pertuzumab — The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore whether 4 courses of dual HER2 blockade combined with taxanes can lead to a similar prognosis with current standard treatment, which is one-year trastuzumab monotherapy combined with chemotherapy, while reducing the adverse reactions of treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or ihc 2+ and fish-positive)
Disease stage
Required: Stage PT1
pT1, pN0, and M0 disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: endocrine therapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: biotherapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: radiation therapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: neoadjuvant treatment
Receiving neoadjuvant treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify